



Non-Proteinogenic Amino Acids in Lacticin 481 Analogues Result in More Potent Inhibition of Peptidoglycan Transglycosylation

Citation

Knerr, Patrick J., Trent J. Oman, Chantal V. Garcia De Gonzalo, Tania J. Lupoli, Suzanne Walker, and Wilfred A. van der Donk. 2012. Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation. *ACS Chemical Biology* 7(11): 1791-1795.

Published Version

doi:10.1021/cb300372b

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:10646332>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Non-proteinogenic Amino Acids in Lacticin 481 Analogues Result in More Potent Inhibition of Peptidoglycan Transglycosylation


Patrick J. Knerr,^{†,⊥} Trent J. Oman,^{†,⊥} Chantal V. Garcia De Gonzalo,[†] Tania J. Lupoli,[‡] Suzanne Walker,[§] and Wilfred A. van der Donk^{*,†}

[†]Howard Hughes Medical Institute and Roger Adams Laboratory, Department of Chemistry, University of Illinois at Urbana–Champaign, 600 South Mathews Avenue, Urbana, Illinois 61801, United States

[‡]Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States

[§]Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, United States

ABSTRACT: Lantibiotics are ribosomally synthesized and post-translationally modified peptide natural products that contain the thioether structures lanthionine and methyllanthionine and exert potent antimicrobial activity against Gram-positive bacteria. At present, detailed modes-of-action are only known for a small subset of family members. Lacticin 481, a tricyclic lantibiotic, contains a lipid II binding motif present in related compounds such as mersacidin and nukacin ISK-1. Here, we show that lacticin 481 inhibits PBP1b-catalyzed peptidoglycan formation. Furthermore, we show that changes in potency of analogues of lacticin 481 containing non-proteinogenic amino acids correlate positively with the potency of inhibition of the transglycosylase activity of PBP1b. Thus, lipid II is the likely target of lacticin 481, and use of non-proteinogenic amino acids resulted in stronger inhibition of the target. Additionally, we demonstrate that lacticin 481 does not form pores in the membranes of susceptible bacteria, a common mode-of-action of other lantibiotics.



The increasing application of genome mining to the discovery of novel bioactive compounds has revealed that ribosomally synthesized and post-translationally modified peptides possess a wide diversity of structure and activity.^{1,2} Among the fastest growing families in this class of natural products are the lantibiotics, which are defined by the presence of the cyclic thioether-containing moieties *meso*-lanthionine (Lan) and (2*S*,3*S*,6*R*)-3-methyllanthionine (MeLan).³ These structures are post-translationally generated from a linear precursor peptide containing an N-terminal leader peptide that facilitates the modification of a C-terminal core peptide, which becomes the active species after removal of the leader peptide.⁴ Enzymatic dehydration of serine and threonine residues to 2,3-didehydroalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb), respectively, followed by intramolecular Michael-type addition of a cysteine thiol yields the Lan/MeLan structures. Many lantibiotics possess antimicrobial activity against a range of clinically relevant Gram-positive bacteria, including strains resistant to traditional antibiotics,^{3,5,6} but the molecular details of these activities remain scarce in all but a few cases. The best understood compound is nisin (Figure 1),^{7,8} which uses its N-terminal A- and B-rings to bind the membrane-bound peptidoglycan precursor lipid II,⁹ the same biological target as the clinical antibiotic vancomycin. Once bound, nisin sequesters lipid II to prevent transglycosylation involved in peptidoglycan biosynthesis¹⁰ and also inserts its C-terminal ring system into the membrane to form pores.^{11,12} An alternative binding interaction with lipid II has been described

for mersacidin (Figure 1), which inhibits transglycosylation but does not form pores.^{13–15}

Lacticin 481 (Figure 1) is a tricyclic class II lantibiotic first isolated in the early 1990s from *Lactococcus lactis* subsp. *lactis* CNRZ 481.¹⁶ This natural product demonstrates inhibitory activity against the indicator strain *L. lactis* subsp. *cremoris* HP (IC₅₀ = 785 nM; MIC = 1,560 nM),¹⁷ but this activity is modest compared to more potent lantibiotics such as nisin (IC₅₀ = 14 nM; MIC = 32 nM).¹⁸ A variety of natural analogues containing a ring topology similar to that of lacticin 481, including nukacin ISK-1 and members of the salivaricin family, have since been isolated from other Gram-positive organisms and exhibit varied antimicrobial scope and potency.¹⁹ Although the ring topology of these compounds is quite different from other lipid II binding lantibiotics, these peptides appear to contain the mersacidin-like lipid II binding motif within their A-ring (Figure 1). Until recently, the mechanism-of-action of this subclass of lantibiotics was largely unexplored. The first evidence that lacticin 481 may form complexes with lipid II was provided in 2009 using thin-layer chromatography.¹⁴ More recently, the binding interaction between lipid II and nukacin ISK-1, a seven-residue natural variant of lacticin 481 with an identical ring topology, has been documented using isothermal titration calorimetry.²⁰ These experiments suggest that lacticin

Received: July 18, 2012

Accepted: August 24, 2012

Published: August 24, 2012




Figure 1. Sequences and ring topologies of nisin, mersacidin, and lactacin 481, highlighting the known lipid II binding motifs of nisin (blue circle) and mersacidin (red circle). The chemical structures of the post-translational modifications found in these natural products are also shown.

481 likely exerts its biological activity *via* interaction with lipid II.

We have recently reported the generation of a series of mutants of lactacin 481 with altered antimicrobial potencies using an *in vitro* biosynthetic platform.^{17,21} The analogues had both improved and attenuated activities, but the underlying mechanism for the changes in bioactivities is unknown and could involve differences in uptake, metabolism, or interaction with the target. In this study, we used the *in vitro* methodology¹⁷ to produce sufficient quantities of four analogues for further mode-of-action studies. These compounds contained the following mutations: N15R/F21H, N15R/F21Pal, N15R/F21H/W23Nal, and N15R/F21Pal/W23Nal, where Pal = 3-(4'-pyridyl)alanine and Nal = 3-(2-naphthyl)alanine. Previous evaluation of these analogues against *L. lactis* HP demonstrated that the N15R/F21Pal ($IC_{50} = 213 \pm 9$ nM) and N15R/F21H ($IC_{50} = 428 \pm 21$ nM) analogues displayed more potent growth inhibitory activity compared to authentic lactacin 481 ($IC_{50} = 785 \pm 19$ nM). The triply substituted analogues N15R/F21H/W23Nal ($IC_{50} = 1370 \pm 48$ nM) and N15R/F21Pal/W23Nal ($IC_{50} = 2420 \pm 60$ nM) were less active than the natural product, thus yielding an IC_{50} value range from 200 to 2500 nM with authentic lactacin 481 as the median.¹⁷

We examined in this work whether changes in inhibitory activity could be correlated with a biochemical mode-of-action. Given the recently reported binding of nukacin ISK-1 to lipid II,²⁰ we specifically examined if lactacin 481 inhibits the transglycosylation reaction involved in peptidoglycan biosynthesis. We used a previously reported *in vitro* assay that monitors the catalytic activity of a major transglycosylase, PBP1b, from *Escherichia coli* using a radiolabeled lipid II variant as substrate.²² The two lactacin 481 analogues with improved antibacterial activity compared to that of the wild type compound also displayed an enhanced inhibitory effect on the transglycosylation reaction (Figure 2), with IC_{50} values of




Figure 2. Inhibition of PBP1b-catalyzed peptidoglycan (PG) formation by lactacin 481 and analogues produced *in vitro*, at a lipid II concentration of 4 μ M and a PBP1b concentration of 100 nM. Error bars represent the standard deviation from triplicate experiments. Black squares: authentic lactacin 481; red triangles: N15R/F21H; green circles: N15R/F21Pal; pink diamonds: N15R/W19Nal/F21H; blue stars: N15R/W19Nal/F21Pal.

5.4 ± 1.2 and 7.0 ± 2.9 μ M for N15R/F21Pal and N15R/F21H, respectively, compared to an IC_{50} of 12 ± 2.3 μ M for wild-type lactacin 481. Likewise, the two less active analogues gave weaker inhibition with IC_{50} values of 27 ± 5.6 and 105 ± 34 μ M for N15R/F21H/W23Nal and N15R/F21Pal/W23Nal, respectively. These IC_{50} values are higher than those for antimicrobial activity because these lantibiotics bind to the substrate, not the biosynthetic enzyme, and because of the relatively high concentrations of lipid II required for these assays compared to lipid II present in cell membranes. Importantly, the potency of transglycosylase inhibition observed for lactacin 481 is similar to that of the known lipid II binders haloduracin²³ and ramoplanin²⁴ using the same assay, suggesting that like these compounds, the binding affinity is in the mid-nanomolar range. Furthermore, the positive correlation between antimicrobial activity and transglycosylation inhibition in the series of analogues strongly suggests that lactacin 481 exerts its biological activity through inhibition of cell wall biosynthesis.

The mersacidin-like lipid II binding motif (TXS/TXD/EC, where X is any residue) is found in ring A of lactacin 481 (Figure 1) as well as other lantibiotics known to interact with lipid II,²⁵ including the α -peptides of two-component systems such as lactacin 3147²⁶ and haloduracin.^{18,23} The importance of

the conserved acidic residue in this motif for antimicrobial potency has been demonstrated in several instances, where mutation to a nonacidic residue abolishes or severely attenuates activity.^{23,27–30} It was therefore surprising that a previous study suggested that the conserved glutamate (Glu13) in the A-ring of lacticin 481 was not required for antimicrobial activity, because a weak zone of growth inhibition was seen for the E13A mutant that also lacked Lys1.³¹ Using our recently developed *in vitro* methodology,¹⁷ we prepared wild type lacticin 481 and an E13A mutant containing Lys1 and tested their activity against *L. lactis* HP. Whereas the zone of growth inhibition observed for the wild type compound prepared *in vitro* was very similar to that of authentic lacticin 481 isolated from the producer strain, the E13A mutant did not show any zone of growth inhibition. Therefore, Glu13 is important for the antimicrobial activity of lacticin 481,³² similar to previous results for other lantibiotics containing the mersacidin-like lipid II binding motif.

In addition to inhibition of peptidoglycan biosynthesis, several lantibiotics are known to form pores in bacterial membranes using lipid II as a docking molecule, including nisin^{11,12} and the two-component systems lacticin 3147²⁶ and haloduracin.^{18,23} To investigate if lacticin 481 is similarly able to form pores once bound to lipid II, we used flow cytometry to monitor changes in bacterial membrane polarization using the potential-sensitive fluorescent dye 3,3'-diethyloxycarbocyanine iodide (DiOC₂(3)). We chose to use *Bacillus subtilis* ATCC 6633 in these experiments because lacticin 481 (IC₅₀ = 980 ± 110 nM) possesses antimicrobial potency relatively similar to that of nisin (IC₅₀ = 410 ± 170 nM)¹⁸ against this organism. As expected, nisin gave a marked concentration-dependent decrease in cell-associated mean fluorescent intensity (MFI), which is indicative of membrane depolarization due to pore formation (Figure 3). However, lacticin 481 did not decrease the MFI at concentrations up to 20 μM when compared to a control sample. We also probed potential membrane disruption by lacticin 481 in *L. lactis* HP using the fluorescent dye propidium iodide (PI), which cannot cross intact cell membranes and enters cells only in the presence of a pore-forming agent. Nisin used at 0.2 μM (15-fold above its IC₅₀ value for this strain) gave a large increase in cell-associated MFI, consistent with pore formation and loss of membrane integrity (Figure 4). On the other hand, lacticin 481 was not able to increase the MFI above control levels at concentrations up to 20 μM, or 25-fold above its IC₅₀ value. Taken together, these data suggest that lacticin 481 is not able to form pores in bacterial membranes. This conclusion may partially explain the modest activity of lacticin 481 compared to nisin against certain bacterial strains, such as *L. lactis*. Analogously, in two-component lantibiotics, the α-peptide binds lipid II and bears modest antimicrobial activity, but subsequent complex formation with the β-peptide results in pore formation and a 50- to 100-fold increase in potency,^{18,26} which is comparable to the ratio of activity between lacticin 481 and nisin against *L. lactis* HP.

In conclusion, lacticin 481 binds to lipid II and inhibits the transglycosylation reaction necessary for cell wall formation. The antimicrobial potency of a series of analogues demonstrated a clear positive correlation with inhibition of transglycosylation, indicating that the improved antimicrobial activities imparted by the introduction of non-natural amino acids resulted in an increased affinity to its target. These observations bode well for the use of non-proteinogenic amino




Figure 3. Membrane depolarization activities of nisin and lacticin 481 against *Bacillus subtilis* measured using DiOC₂(3) fluorescence. (a) Average mean fluorescence intensity (MFI) of triplicate measurements for different concentrations of lacticin 481 (blue) and the known pore-forming lantibiotic nisin (red). At each concentration, the difference in MFI between the compounds was statistically significant ($P < 0.05$). (b) Representative histogram of cell count versus DiOC₂(3) fluorescence intensity at various lacticin 481 and nisin concentrations.

acids to improve lantibiotics *via* molecular editing. Unlike nisin, lacticin 481 is not able to form pores in bacterial membranes, which may contribute to its modest activity against some bacterial strains compared to nisin.

METHODS

General Materials and Methods. Cell culture media were purchased from BD Biosciences. The indicator strain *Lactococcus lactis* subsp. *cremoris* HP ATCC 11602 was obtained from American Type Culture Collection. Flow cytometry dyes 3,3'-diethyloxycarbocyanine iodide (DiOC₂(3)) and propidium iodide (PI) were purchased from Invitrogen. Nisin was purified from Nisaplin, purchased from Danisco A/S, as previously described.¹⁸ Lacticin 481 was purified from cultures of the producing organism *L. lactis* subsp. *lactis* CNRZ 481 as previously described.¹⁷

Chemoenzymatic Synthesis of Lacticin 481 Analogues. Lacticin 481 analogues were prepared as previously described.¹⁷ Briefly, a constitutively active leader-LctM fusion enzyme (LctCE-GS₁₅) was expressed in *Escherichia coli* Rosetta 2 (DE3) and purified by immobilized metal ion affinity chromatography and gel filtration chromatography. Linear lacticin 481 core peptide analogues were prepared via Fmoc-based solid-phase peptide synthesis and purified to homogeneity by reversed-phase high performance liquid chromatography (RP-HPLC). These core peptide analogues (20 μM) were incubated with LctCE-GS₁₅ (2 μM) in a buffer containing tris(hydroxymethyl)aminomethane (50 mM, pH 7.5), MgCl₂ (10 mM), and ATP (2 mM) for 5–12 h and purified by RP-HPLC to yield




Figure 4. Unlike nisin, lactacin 481 does not alter the membrane permeability of *Lactococcus lactis* HP as measured by propidium iodide (PI) uptake. (a) Average MFI of triplicate measurements for nisin at a concentration 15-fold above its IC_{50} value and a range of lactacin 481 concentrations up to 25-fold above its IC_{50} value. (b) Representative histogram of cell count versus PI fluorescence intensity at antibiotic concentrations shown in panel a.

the pure, fully modified peptides as determined by MALDI-TOF MS analysis. HPLC solvent compositions: solvent A was 0.1% trifluoroacetic acid in H_2O (v/v); solvent B was 4:1 acetonitrile/ H_2O (v/v) with 0.087% trifluoroacetic acid.

LctA core wild type. Sequence: H-KGGSGVIHTISH-ECNMNSWQFVFTCCS-OH. RP-HPLC: Phenomenex Jupiter Pro-teo C₁₂ column (250 mm \times 15 mm \times 10 μ m) using a flow rate of 10 mL/min and a solvent gradient of 10% solvent B for 1 min, 10–20% B over 3 min, 20–48% B over 28 min, 48–100% B over 1 min. t_R = 28.3–29.1 min. HRMS (MALDI-TOF): calculated $[M + H]^+$ for C₁₂₇H₁₉₁N₃₆O₃₉S₄ 2972.295, found 2972.444 (unmodified precursor); calculated $[M + H]^+$ for C₁₂₇H₁₈₃N₃₆O₃₃S₄ 2900.250, found 2900.385 (modified product).

LctA core E13A. RP-HPLC: same conditions as LctA core wild type. t_R = 28.9–29.6 min. HRMS (MALDI-TOF): calculated $[M + H]^+$ for C₁₂₅H₁₈₉N₃₆O₃₇S₄ 2914.289, found 2914.246 (unmodified precursor); calculated $[M + H]^+$ for C₁₂₅H₁₈₁N₃₆O₃₃S₄ 2842.244, found 2842.349 (modified product).

PBP1b Transglycosylation Assays. The gene encoding *Escherichia coli* PBP1b, previously amplified from MG1655 genomic DNA, was expressed as a C-terminal hexa-histidine (His₆) fusion protein and purified as previously described.²² A [¹⁴C]GlcNAc-labeled heptaprenyl lipid II analogue was prepared via a chemoenzymatic route by Dr. Yuto Sumida and Dr. Hiro Tsukamoto (Dan Kahne laboratory, Harvard University) as previously described.³³ The [¹⁴C]GlcNAc-labeled heptaprenyl lipid II analogue (4 μ M; typical specific activity = 288 μ Ci μ mol⁻¹) and varying concentrations of lactacin 481 or analogues were used for a PBP1b assay as previously described.²³

Flow Cytometry Analysis of Membrane Disruption. For membrane potential assays using the dye 3,3'-diethyloxycarbocyanine iodide (DiOC₂(3)),¹⁸ cultures of *Bacillus subtilis* ATCC 6633 were grown overnight at 37 °C in LB medium and then diluted with fresh LB to an OD₆₀₀ of 0.1. Cells were combined with DiOC₂(3) (final concentration 2 μ M), HEPES (1 mM) and glucose (1 mM) and incubated for 20 min at RT. Stock solutions of nisin or lactacin 481 were added to final concentrations of 0.2, 2.0, and 20 μ M and incubated for an additional 15 min prior to analysis; H_2O was added instead of antibiotic as a negative control. Changes in cell-associated DiOC₂(3) fluorescence were measured with a BD Biosciences LSR II flow cytometer, using excitation at 488 nm with an argon laser and measurement of emission through a band-pass filter at 530/30 nm. A minimum of 50,000 events were detected for each sample, and experiments were performed in triplicate. Data analysis to calculate the geometric mean fluorescence intensity (MFI) of gated cell populations was performed using FCS Express 3.00.0311 V Lite Stand-alone software. For membrane permeability assays using the dye propidium iodide (PI),³⁴ cultures of *Lactococcus lactis* subsp. *cremoris* HP were grown overnight at 30 °C in GM17 medium (40 g L⁻¹ M17, 0.5% glucose (w/v)) and then diluted with fresh GM17 to an optical density at 600 nm (OD₆₀₀) of 0.1. Cells were combined with PI (final concentration 25 μ M), HEPES (1 mM), glucose (1 mM), and lactacin 481 (0, 0.2, 2.0, 20 μ M) or nisin (0.2 μ M), incubated for 15 min at RT, and analyzed. Data acquisition and analysis were performed as for membrane potential assays, except emission was measured through a band-pass filter at 695/40 nm.

AUTHOR INFORMATION

Corresponding Author

*E-mail: vddonk@illinois.edu.

Author Contributions

[†]These authors contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health (GM58822 to W.A.V.; GM067610 to S.W.), the Robert C. and Carolyn J. Springborn Endowment (to P.J.K.), an American Heart Association Midwest Affiliate predoctoral fellowship (11PRE7620039 to P.J.K.), and a National Institutes of Health Cellular and Molecular Biology training grant (T32 GM007283 to T.J.O.).

REFERENCES

- (1) Velásquez, J. E., and van der Donk, W. A. (2011) Genome mining for ribosomally synthesized natural products. *Curr. Opin. Chem. Biol.* 15, 11–21.
- (2) McIntosh, J. A., Donia, M. S., and Schmidt, E. W. (2009) Ribosomal peptide natural products: Bridging the ribosomal and nonribosomal worlds. *Nat. Prod. Rep.* 26, 537–559.
- (3) Knerr, P. J., and van der Donk, W. A. (2012) Discovery, biosynthesis, and engineering of lantipeptides. *Annu. Rev. Biochem.* 81, 479–505.
- (4) Oman, T. J., and van der Donk, W. A. (2010) Follow the leader: the use of leader peptides to guide natural product biosynthesis. *Nat. Chem. Biol.* 6, 9–18.
- (5) Bierbaum, G., and Sahl, H. G. (2009) Lantibiotics: mode of action, biosynthesis and bioengineering. *Curr. Pharm. Biotechnol.* 10, 2–18.
- (6) Cotter, P. D., Hill, C., and Ross, R. P. (2005) Bacterial lantibiotics: strategies to improve therapeutic potential. *Curr. Protein Pept. Sci.* 6, 61–75.
- (7) Breukink, E., and de Kruijff, B. (2006) Lipid II as a target for antibiotics. *Nat. Rev. Drug Discovery* 5, 321–332.

- (8) Schneider, T., and Sahl, H. G. (2010) Lipid II and other bactoprenol-bound cell wall precursors as drug targets. *Curr. Opin. Invest. Drugs* 11, 157–164.
- (9) Hsu, S.-T. D., Breukink, E., Tischenko, E., Lutters, M. A. G., de Kruijff, B., Kaptein, R., Bonvin, A. M. J. J., and van Nuland, N. A. J. (2004) The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. *Nat. Struct. Mol. Biol.* 11, 963–967.
- (10) Hasper, H. E., Kramer, N. E., Smith, J. L., Hillman, J. D., Zachariah, C., Kuipers, O. P., de Kruijff, B., and Breukink, E. (2006) An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. *Science* 313, 1636–1637.
- (11) Hasper, H. E., de Kruijff, B., and Breukink, E. (2004) Assembly and stability of nisin-lipid II pores. *Biochemistry* 43, 11567–11575.
- (12) Wiedemann, I., Benz, R., and Sahl, H.-G. (2004) Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. *J. Bacteriol.* 186, 3259–3261.
- (13) Brötz, H., Bierbaum, G., Leopold, K., Reynolds, P. E., and Sahl, H. G. (1998) The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. *Antimicrob. Agents Chemother.* 42, 154–160.
- (14) Böttiger, T., Schneider, T., Martínez, B., Sahl, H.-G., and Wiedemann, I. (2009) Influence of Ca^{2+} ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif. *Appl. Environ. Microbiol.* 75, 4427–4434.
- (15) Hsu, S.-T. D., Breukink, E., Bierbaum, G., Sahl, H.-G., de Kruijff, B., Kaptein, R., van Nuland, N. A. J., and Bonvin, A. M. J. J. (2003) NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles: Conformational changes are a key to antimicrobial activity. *J. Biol. Chem.* 278, 13110–13117.
- (16) Piard, J. C., Muriana, P. M., Desmazeaud, M. J., and Klaenhammer, T. R. (1992) Purification and partial characterization of lacticin 481, a lanthionine-containing bacteriocin produced by *Lactococcus lactis* subsp. *lactis* CNRZ 481. *Appl. Environ. Microbiol.* 58, 279–284.
- (17) Oman, T. J., Knerr, P. J., Bindman, N. A., Velásquez, J. E., and van der Donk, W. A. (2012) An engineered lantibiotic synthetase that does not require a leader peptide on its substrate. *J. Am. Chem. Soc.* 134, 6952–6955.
- (18) Oman, T. J., and van der Donk, W. A. (2009) Insights into the mode of action of the two-peptide lantibiotic haloduracin. *ACS Chem. Biol.* 4, 865–874.
- (19) Dufour, A., Hindré, T., Haras, D., and Le Pennec, J.-P. (2007) The biology of lantibiotics from the lacticin 481 group is coming of age. *FEMS Microbiol. Rev.* 31, 134–167.
- (20) Islam, M. R., Nishie, M., Nagao, J.-i., Zendo, T., Keller, S., Nakayama, J., Kohda, D., Sahl, H.-G., and Sonomoto, K. (2012) Ring A of nukacin ISK-1: A lipid II-binding motif for type-A(II) lantibiotic. *J. Am. Chem. Soc.* 134, 3687–3690.
- (21) Levengood, M. R., Knerr, P. J., Oman, T. J., and van der Donk, W. A. (2009) In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids. *J. Am. Chem. Soc.* 131, 12024–12025.
- (22) Chen, L., Walker, D., Sun, B., Hu, Y., Walker, S., and Kahne, D. (2003) Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. *Proc. Natl. Acad. Sci. U.S.A.* 100, 5658–5663.
- (23) Oman, T. J., Lupoli, T. J., Wang, T.-S. A., Kahne, D., Walker, S., and van der Donk, W. A. (2011) Haloduracin α binds the peptidoglycan precursor lipid II with 2:1 stoichiometry. *J. Am. Chem. Soc.* 133, 17544–17547.
- (24) Hu, Y., Helm, J. S., Chen, L., Ye, X.-Y., and Walker, S. (2003) Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II. *J. Am. Chem. Soc.* 125, 8736–8737.
- (25) Wiedemann, I., Böttiger, T., Bonelli, R. R., Schneider, T., Sahl, H.-G., and Martínez, B. (2006) Lipid II-based antimicrobial activity of the lantibiotic plantaricin C. *Appl. Environ. Microbiol.* 72, 2809–2814.
- (26) Wiedemann, I., Böttiger, T., Bonelli, R. R., Wiese, A., Hagge, S. O., Gutsmann, T., Seydel, U., Deegan, L., Hill, C., Ross, P., and Sahl, H.-G. (2006) The mode of action of the lantibiotic lacticin 3147 – a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. *Mol. Microbiol.* 61, 285–296.
- (27) Szekat, C., Jack, R. W., Skutlarek, D., Farber, H., and Bierbaum, G. (2003) Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. *Appl. Environ. Microbiol.* 69, 3777–3783.
- (28) Cooper, L. E., McClerren, A. L., Chary, A., and van der Donk, W. A. (2008) Structure-activity relationship studies of the two-component lantibiotic haloduracin. *Chem. Biol.* 15, 1035–1045.
- (29) Islam, M. R., Shioya, K., Nagao, J., Nishie, M., Jikuya, H., Zendo, T., Nakayama, J., and Sonomoto, K. (2009) Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. *Mol. Microbiol.* 72, 1438–1447.
- (30) Deegan, L. H., Suda, S., Lawton, E. M., Draper, L. A., Hugenholtz, F., Peschel, A., Hill, C., Cotter, P. D., and Ross, R. P. (2010) Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147. *Microb. Biotechnol.* 3, 222–234.
- (31) Patton, G. C., Paul, M., Cooper, L. E., Chatterjee, C., and van der Donk, W. A. (2008) The importance of the leader sequence for directing lanthionine formation in lacticin 481. *Biochemistry* 47, 7342–7351.
- (32) In the previous study (ref 31), the amount of compound used for the bioassay was not quantified, and it is possible that the observed activity was caused by a relatively high concentration of material. Indeed, although the MIC value of the corresponding E22Q mutant of haloduracin α increased 40-fold compared to wild type, the haloduracin mutant did possess antimicrobial activity (ref 23).
- (33) Ye, X.-Y., Lo, M.-C., Brunner, L., Walker, D., Kahne, D., and Walker, S. (2001) Better substrates for bacterial transglycosylases. *J. Am. Chem. Soc.* 123, 3155–3156.
- (34) Gut, I. M., Blanke, S. R., and van der Donk, W. A. (2011) Mechanism of inhibition of *Bacillus anthracis* spore outgrowth by the lantibiotic nisin. *ACS Chem. Biol.* 6, 744–752.